Addex Therapeutics (FRA:APE) Cyclically Adjusted Book per Share: €0.34 (As of Mar. 2026)


What is Addex Therapeutics Cyclically Adjusted Book per Share?

Addex Therapeutics FRA:APE -4.60% Cyclically Adjusted Book per Share is €0.34 as of Mar. 2026. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Addex Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €0.030. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.34 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Addex Therapeutics's average Cyclically Adjusted Book Growth Rate was -40.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-01), Addex Therapeutics's current stock price is €0.0415. Addex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €0.34. Addex Therapeutics's Cyclically Adjusted PB Ratio of today is 0.12.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Addex Therapeutics was 0.14. The lowest was 0.01. And the median was 0.08.


Addex Therapeutics  (FRA:APE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Addex Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.0415/0.34
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Addex Therapeutics was 0.14. The lowest was 0.01. And the median was 0.08.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Addex Therapeutics Cyclically Adjusted Book per Share Related Terms


Addex Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Cyclically Adjusted Book per Share Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 65.98 18.24 0.36

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.63 0.46 0.29 0.36 0.34

FRA:APE vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Addex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Addex Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Cyclically Adjusted PB Ratio falls into.



Addex Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Addex Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.03/107.1957*107.1957
=0.030

Current CPI (Mar. 2026) = 107.1957.

Addex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.251 101.036 0.266
201406 0.171 101.517 0.181
201412 0.195 100.704 0.208
201506 0.238 100.464 0.254
201512 0.139 99.386 0.150
201606 0.095 100.088 0.102
201612 0.018 99.380 0.019
201706 0.165 100.285 0.176
201712 0.086 100.213 0.092
201806 1.386 101.435 1.465
201812 1.317 100.906 1.399
201903 0.000 101.571 0.000
201906 1.092 102.044 1.147
201909 0.000 101.396 0.000
201912 0.879 101.063 0.932
202003 0.770 101.048 0.817
202006 0.658 100.743 0.700
202009 0.551 100.585 0.587
202012 0.498 100.241 0.533
202103 0.549 100.800 0.584
202106 0.440 101.352 0.465
202109 0.360 101.533 0.380
202112 0.429 101.776 0.452
202203 0.334 103.205 0.347
202206 0.177 104.783 0.181
202209 0.155 104.835 0.158
202212 0.065 104.666 0.067
202303 0.051 106.245 0.051
202306 0.068 106.576 0.068
202309 0.042 106.570 0.042
202312 0.013 106.461 0.013
202403 -0.014 107.355 -0.014
202406 0.134 107.991 0.133
202409 0.120 107.468 0.120
202412 0.105 107.128 0.105
202503 0.088 107.722 0.088
202506 0.069 108.075 0.068
202509 0.055 107.709 0.055
202512 0.043 107.196 0.043
202603 0.030 107.196 0.030

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.34 mean?
Addex Therapeutics (FRA:APE) has a Cyclically Adjusted Book per Share of €0.34 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' Cyclically Adjusted Book per Share too high?
Addex Therapeutics' current Cyclically Adjusted Book per Share is €0.34.
How does Addex Therapeutics' Cyclically Adjusted Book per Share compare to VRTX and REGN?
Addex Therapeutics' Cyclically Adjusted Book per Share of €0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Cyclically Adjusted Book per Share is €0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Addex Therapeutics (FRA:APE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.04 — trading 315% above its estimated fair value. The current Cyclically Adjusted Book per Share is €0.34. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current Cyclically Adjusted Book per Share is €0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.